Iq-ai Share Discussion Threads

[herb clark] 13/6/2019 09:03

Do they have FDA approval?

[tidy 2] 13/6/2019 09:02

Watch the interview 100% very soon. FDA are happy and they have the best on the case 100% approval rate.

[ashtree2] 13/6/2019 09:01

FDA approval needs to be confirmed cos you cant sell it without it.

[hazl] 13/6/2019 08:58

It would make a lot of difference,the news we have been waiting for.
Let's hope for the best.

[tidy 2] 13/6/2019 08:56

Yesterdays interview says 100% approval now ready to be given. Best in the business involved with 100% success rate.

[hazl] 13/6/2019 08:55

Herb I hope so I bought a while back.

[soupdragon55] 13/6/2019 08:52

2m cap now. 120m shares in issue as per the company website.

Still can see a good amount ahead.

[herb clark] 13/6/2019 08:51

Are these worth buying given today's rise?

[hazl] 13/6/2019 08:50

It's about the FDA approval.

That is the important catalyst.

[tidy 2] 13/6/2019 08:43

1m cap now. If this matches NFX as expected its a 52 bag from here.

[tidy 2] 13/6/2019 08:40

Market delay picking up on the news here. Waking up today.

[tidy 2] 13/6/2019 08:38

Massive approval watch that interview link. 100% very confidently very soon.

[leadersoffice] 13/6/2019 08:35

The only thing I forgot to do is buy them in my share ISA. Along with NFX might have to do a bed & breakfast. Ah well, hold fire

[leadersoffice] 13/6/2019 08:32

There's results on a trial due imminently?

[leadersoffice] 13/6/2019 08:31

Thanks. Listened to the interview on pro active investors last night

[tidy 2] 13/6/2019 08:31

Yesterdays interview expect big news very soon on top of yesterdays sales agreement. htTps://youtu.be/6BCSZIi5VQE

[hazl] 13/6/2019 08:29

Yes it's got a more promising feel to it now.
Let's hope for good news soon!

[parsons4] 13/6/2019 08:26

Just topped up , had to pay 1.5 though. The upside here is the low market cap and the downside the need for more capital all IMHO of course.

[tidy 2] 13/6/2019 08:23

From this cap it has more upside than NFX for sure. 880k cap 67m shares in issue. Worldwide sales agreement and sales started and open up to existing cor-tech clients.

[leadersoffice] 13/6/2019 08:20

I'm in.Just invested my gains from the past 3 weeks from TCG in here. Fingers crossed. If it's another NFX.... should do well!!

[tidy 2] 13/6/2019 08:17

Door opened to Worldwide growth. David Smith, IB's chief executive, said the deal meant IQ-AI's products would have "direct sales representation worldwide" for the first time, and that the firm was "very excited" about the shared revenue potential of the agreement."CorTechs Labs has a well established and rapidly growing sales and marketing team who can introduce IB's portfolio to their existing and new clients", he added.

[tidy 2] 12/6/2019 22:08

IQ-AI surges as Imaging Biometrics signs business development deal with CorTechs Labs2019-06-12 08:14:00The medical software and services group said the agreement would provide its products with "extended and immediate" sales representation in the US and other international marketsHandshakeIQ-AI said IB's products would complement those of CorTechs, which specialises in assessing neurological conditions IQ-AI Limited's (LON:IQAI) shares surged on Wednesday after its subsidiary, Imaging Biometrics (IB), signed a non-exclusive business development and sales deal with brain analysis firm CorTechs Labs.The medical software and services group said the agreement would provide its products with "extended and immediate" sales representation in the US and other international markets, while CorTech would add IB's software and exclusive algorithms to its portfolio.READ: IQ-AI's Imaging Biometrics featured in American Journal of Neuro RadiologyThe product suite includes IB's StoneChecker software, which helps analyse kidney stones, as well as IB Neuro which provides tumour biology data and the IB Delta Suite which helps clinicians distinguish tumour progression from treatment effects.IQ-AI said IB's products would complement those of CorTechs, which specialises in assessing neurological conditions, including Alzheimer's disease, multiple sclerosis, epilepsy and traumatic brain injury.David Smith, IB's chief executive, said the deal meant IQ-AI's products would have "direct sales representation worldwide" for the first time, and that the firm was "very excited" about the shared revenue potential of the agreement."CorTechs Labs has a well established and rapidly growing sales and marketing team who can introduce IB's portfolio to their existing and new clients", he added.htTps://www.google.co.uk/amp/s/www.proactiveinvestors.co.uk/companies/amp/news/221946

[tidy 2] 12/6/2019 19:35

NFX No2 found here. Imo.

[hedgehog 100] 12/6/2019 18:34

Soupdragon5512 Jun '19 - 15:51 - 269 of 275
"StoneChecker FDA comment
Product was enhanced and resubmitted, FDA have no further questions, so now just in queue waiting for approval to come through.
They've used the most experienced regulatory consultant to submit the FDA and say that the CorTech deal shows how positive they are that they'll soon get FDA."


You can't over-emphasise the importance of that "no further questions" info.

The FDA seem to have come back endlessly with queries, each time stopping the '90 day clock'.

It's been a lengthy and frustrating process, which has hit the IQAI share price hard.
But now it looks like the process is all but over.

The FDA are finally satisfied, and it's now just the final admin. that needs to be done before their approval is given.